Edgewise Therapeutics (EWTX) Competitors $13.84 -0.03 (-0.22%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$13.36 -0.48 (-3.50%) As of 07/11/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. TLX, AXSM, CRSP, ADMA, PCVX, RYTM, CYTK, KRYS, AKRO, and ZLABShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), ADMA Biologics (ADMA), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Its Competitors Telix Pharmaceuticals Axsome Therapeutics CRISPR Therapeutics ADMA Biologics Vaxcyte Rhythm Pharmaceuticals Cytokinetics Krystal Biotech Akero Therapeutics Zai Lab Telix Pharmaceuticals (NASDAQ:TLX) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings. Is TLX or EWTX more profitable? Telix Pharmaceuticals' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A Edgewise Therapeutics N/A -30.95%-29.45% Which has preferable earnings and valuation, TLX or EWTX? Telix Pharmaceuticals has higher revenue and earnings than Edgewise Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$516.72M10.46$32.93MN/AN/AEdgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.93 Do analysts prefer TLX or EWTX? Telix Pharmaceuticals presently has a consensus target price of $22.33, indicating a potential upside of 39.85%. Edgewise Therapeutics has a consensus target price of $40.00, indicating a potential upside of 189.02%. Given Edgewise Therapeutics' higher possible upside, analysts clearly believe Edgewise Therapeutics is more favorable than Telix Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer TLX or EWTX? In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 9 mentions for Telix Pharmaceuticals and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.73 beat Telix Pharmaceuticals' score of 0.66 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTelix Pharmaceuticals beats Edgewise Therapeutics on 6 of the 9 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.46B$2.99B$5.60B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-8.9320.5827.9620.25Price / SalesN/A291.28430.5799.61Price / CashN/A42.8637.4658.16Price / Book2.867.638.045.49Net Income-$133.81M-$55.05M$3.18B$250.27M7 Day Performance6.83%8.39%3.63%4.75%1 Month Performance-10.25%5.35%4.04%7.64%1 Year Performance-38.27%1.95%29.56%16.34% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics1.5135 of 5 stars$13.84-0.2%$40.00+189.0%-38.0%$1.46BN/A-8.9360TLXTelix PharmaceuticalsN/A$15.48-3.7%$22.33+44.3%N/A$5.44B$516.72M0.00N/ANews CoverageAnalyst ForecastAXSMAxsome Therapeutics4.7401 of 5 stars$107.50+2.0%$172.33+60.3%+28.9%$5.19B$385.69M-18.63380CRSPCRISPR Therapeutics3.2397 of 5 stars$51.19-1.9%$71.75+40.2%0.0%$4.51B$37.31M-11.33460Analyst ForecastOptions VolumeADMAADMA Biologics3.9558 of 5 stars$17.88-2.2%$27.67+54.7%+50.4%$4.36B$426.45M21.04530Positive NewsPCVXVaxcyte1.8116 of 5 stars$32.00-3.8%$136.50+326.6%-56.2%$4.29BN/A-8.02160News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.1697 of 5 stars$66.39+0.9%$78.07+17.6%+86.1%$4.18B$130.13M-23.63140Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionCYTKCytokinetics4.0728 of 5 stars$33.36-3.8%$70.92+112.6%-34.3%$4.14B$18.47M-6.31250KRYSKrystal Biotech4.6785 of 5 stars$139.74-2.3%$211.13+51.1%-25.3%$4.13B$290.52M33.59210Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionAKROAkero Therapeutics3.396 of 5 stars$51.52-0.5%$82.50+60.1%+107.6%$4.13BN/A-26.4230Insider TradeZLABZai Lab3.0657 of 5 stars$35.48-2.5%$54.28+53.0%+83.5%$4.04B$398.99M-14.251,869 Related Companies and Tools Related Companies Telix Pharmaceuticals Competitors Axsome Therapeutics Competitors CRISPR Therapeutics Competitors ADMA Biologics Competitors Vaxcyte Competitors Rhythm Pharmaceuticals Competitors Cytokinetics Competitors Krystal Biotech Competitors Akero Therapeutics Competitors Zai Lab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
